Classifications: antineoplastic; hormone; anabolic steroid;
Therapeutic: antineoplastic; anabolic steroid

Pregnancy Category: C
Controlled Substance: Schedule III


50 mg tablets


Chemotherapeutic agent with chemical configuration similar to certain androgens but devoid of androgenic activity (virilization) in therapeutic doses. In breast cancer, effect may result from depression of ovarian function by inhibition of synthesis of pituitary gonadotropin.

Therapeutic Effect

Effectiveness indicated by decrease in size of tumor; more than 50% of nonosseous lesions decrease in size even though all bone lesions remain static.


Adjunctive treatment in palliation of breast carcinoma in postmenopausal women when hormone therapy is indicated. Also effective in women diagnosed before menopause in whom ovarian function has been subsequently terminated.


Premenopausal women; breast cancer in males; pregnancy (category C), lactation.

Cautious Use

Hypercalcemia; cardiorenal disease.

Route & Dosage

Adjunctive Therapy for Breast Cancer
Adult: PO 250 mg q.i.d.


  • Note: If anticoagulants are concurrently ordered, dose is usually reduced when testolactone is initiated.
  • Store at 15°–30° C (59°–86° F) unless otherwise directed. Protect from freezing.

Adverse Effects (≥1%)

CNS: Paresthesias. Endocrine: Deepening of the voice, acne, facial hair growth, clitoral enlargement. GI: Glossitis, anorexia; nausea, vomiting. CV: Hypertension, edema in extremities.

Diagnostic Test Interference

Urinary 17-OHCS determinations may be elevated.


Drug: May enhance hypoprothrombinemic effects of oral anticoagulants.


Absorption: Readily from GI tract. Metabolism: In liver. Elimination: In urine.

Nursing Implications

Assessment & Drug Effects

  • Monitor therapeutic effectiveness. Clinical response usually occurs in 6–12 wk.
  • Lab tests: Check plasma calcium levels periodically (normal serum calcium: 8.5–10.6 mg/dL).
  • Monitor PT and INR carefully with concurrent anticoagulant therapy.
  • Report S&S that suggest impending hypercalcemia (see Appendix F).
  • Monitor I&O ratio and pattern.
  • Encourage patient mobility if feasible; if not, assist with passive exercises.

Patient & Family Education

  • Drug treatment is usually continued for a minimum of 3 mo to evaluate response (unless there is active progression of the disease).
  • Be aware that hypercalcemia represents active remission of bone metastasis; if it occurs, appropriate therapy is instituted.

Common adverse effects in italic, life-threatening effects underlined; generic names in bold; classifications in SMALL CAPS; Canadian drug name; Prototype drug

© 2006-2022 medpill.info Last Updated On: 11/20/2022 (0)
Wait 20 seconds...!!!